Mauna Kea Technologies is developing Cellvizio, a tiny confocal laser microscopy system small enough to be inserted into the colon, the urinary tract, the lungs, deep in the brain, and other small spaces in the body. Today, every procedure in gastroenterology--a biopsy or a therapeutic intervention-- is already the second, third, or later step in a process that becomes cumbersome simply because clinicians can't get the relevant information from the first step, which is endoscopy. That's where Cellvizio brings advantages, providing a real-time, in vivo microscopic image of tissue to properly characterize it, so a gastroenterologist can both determine and efficiently carry out the proper course of treatment for a particular patient. Cellvizio's most compelling initial applications include the diagnosis of biliary strictures, Barrett's Esophagus, and colonoscopy.
9 rue d’Enghien
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.
Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.
Medtech Insight sat down with Jared Bunch, chair of AF Center of Excellence Task Force, at HRS 2025 to discuss the newly HRS released framework for Afib Center of Excellence and get his perspective on the role industry could play to help clinicians improve patient outcomes.
